Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

abstract：:Along with the establishment of more intense chemotherapeutic regimens including fludarabine for the treatment of indolent lymphoproliferative diseases like chronic lymphocytic leukemia (CLL), an increasing amount of cases with progressive multifocal leukoencephalopathy (PML) due to JC virus have been observed. We rep...

journal_title：Leukemia & lymphoma

authors： Kiewe P,Seyfert S,Körper S,Rieger K,Thiel E,Knauf W

更新日期：2003-10-01 00:00:00

abstract：:Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...

journal_title：Leukemia & lymphoma

authors： Ellis M,Krashin E,Hamburger-Avnery O,Gan S,Elis A,Ashur-Fabian O

更新日期：2017-05-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide ...

journal_title：Leukemia & lymphoma

authors： Montefusco V,Galli M,Spina F,Stefanoni P,Mussetti A,Perrone G,De Philippis C,Dalto S,Maura F,Bonini C,Rezzonico F,Pennisi M,Roncari L,Soldarini M,Dodero A,Farina L,Cocito F,Caprioli C,Corradini P

更新日期：2014-09-01 00:00:00

abstract：:Bone marrow necrosis (BMN) is a rare pathologic entity associated with a wide variety of diseases. We describe a patient with chronic myeloid leukemia on interferon treatment, who developed BMN with symptoms and signs masquerading as interferon toxicity. This is followed by a literature review of BMN in CML. ...

journal_title：Leukemia & lymphoma

authors： Chim CS,Ma SK,Lam CK

更新日期：1999-04-01 00:00:00

abstract：:Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

journal_title：Leukemia & lymphoma

authors： Goebeler ME,Bargou R

更新日期：2016-05-01 00:00:00

abstract：:A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

journal_title：Leukemia & lymphoma

authors： Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

更新日期：2004-03-01 00:00:00

abstract：:Survival rates for Hodgkin lymphoma and non-Hodgkin lymphoma have improved in recent years. However, these improvements are associated with various late effects, which can compromise health-related quality of life (HRQoL). Improving HRQoL is a significant goal in oncology, and increasingly one of the primary outcomes ...

journal_title：Leukemia & lymphoma

authors： Arden-Close E,Pacey A,Eiser C

更新日期：2010-04-01 00:00:00

abstract：:We evaluated the association of two IL10 single nucleotide polymorphisms (SNPs) (rs1800896 and rs1800871) with non-Hodgkin lymphoma (NHL) risk in the three major races of the Malaysian population (Malay, Chinese and Indian; 317 cases and 330 controls). Our initial screening demonstrated that rs1800871 but not rs180089...

journal_title：Leukemia & lymphoma

authors： Lim YY,Chin YM,Tai MC,Fani S,Chang KM,Ong TC,Bee PC,Gan GG,Ng CC

更新日期：2015-01-01 00:00:00

abstract：:Chronic myelogenous leukaemia (CML) is one of the most intensively studied human malignancies. It has been the focus of major efforts to develop potent drugs for several decades, but until recently cure rates remained low. A breakthrough in CML therapy was very likely accomplished with the clinical introduction of STI...

journal_title：Leukemia & lymphoma

authors： Feller SM,Tuchscherer G,Voss J

更新日期：2003-03-01 00:00:00

abstract：:Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poo...

journal_title：Leukemia & lymphoma

authors： Lishner M,Zemlickis D,Sutcliffe SB,Koren G

更新日期：1994-08-01 00:00:00

abstract：:Human leukemia cells may acquire MDR1/P-glycoprotein-mediated multidrug resistance (MDR) in the course of short-term (within hours) exposure to many stress stimuli. This effect is thought to be associated with the activity of protein kinase C (PKC) (Chaudhary, Roninson, 1992. 1993). However, we show here that cytosine...

journal_title：Leukemia & lymphoma

authors： Shtil AA,Ktitorova OV,Kakpakova ES,Holian O

更新日期：2000-12-01 00:00:00

abstract：:Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

journal_title：Leukemia & lymphoma

authors： Richards SJ,Scott CS

更新日期：1992-08-01 00:00:00

abstract：:Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

journal_title：Leukemia & lymphoma

authors： Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

更新日期：2005-07-01 00:00:00

abstract：:Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictor...

journal_title：Leukemia & lymphoma

authors： Keats JJ,Reiman T,Belch AR,Pilarski LM

更新日期：2006-11-01 00:00:00

abstract：:Mutations of the TP53 tumor suppressor gene, contributing to the development and progression of a wide variety of human malignancies, are found in some of the patients with myelodysplastic syndromes (MDS). Previous reports revealed that TP53 mutations were found in 0-25% of patients with MDS and are closely associated...

journal_title：Leukemia & lymphoma

authors： Misawa S,Horiike S

更新日期：1996-11-01 00:00:00

abstract：:Arsenic trioxide (As2O3) is currently employed as a treatment for relapsed acute promyelocytic leukemia (APL), where it can induce remission in greater than 90% of patients, but is ineffective in patients with non-APL acute myeloid leukemia (AML). As2O3 induces apoptosis in APL cells through mechanisms dependent and i...

journal_title：Leukemia & lymphoma

authors： Coe E,Schimmer AD

更新日期：2008-10-01 00:00:00

abstract：:This study was planned as a phase 3 trial to investigate low-dose fludarabine with or without darbepoetin alfa in older patients with previously untreated or treated chronic lymphocytic leukemia (CLL) and comorbidity. Due to slow recruitment, the study was terminated prematurely after accrual of 97 patients who, on av...

journal_title：Leukemia & lymphoma

authors： Goede V,Busch R,Bahlo J,Chataline V,Kremers S,Müller L,Reschke D,Schlag R,Schmidt B,Vehling-Kaiser U,Wedding U,Stilgenbauer S,Hallek M

更新日期：2016-01-01 00:00:00

abstract：:Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome in a consecutive cohort of 175 patients with aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or Burkitt's lymphoma was encountered. All these patients had obtained a complete remission with ...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Magagnoli M,Frezza G,Prologo G,Gherlinzoni F,Bendandi M,Albertini P,Babini L,D'Alessandro R,Tura S

更新日期：1999-02-01 00:00:00

abstract：:Murine monoclonal antibody (mAb) 7C11 binds to the same cell surface epitope as anti-APO-1 and anti-Fas and reacts specifically with cells transfected with a cDNA encoding the human Fas antigen. Furthermore, incubation with 7C11 causes death of hematopoietic cell lines that express APO-1/Fas but not APO-1/Fas-negative...

journal_title：Leukemia & lymphoma

authors： Robertson MJ,Manley TJ,Pichert G,Cameron C,Cochran KJ,Levine H,Ritz J

更新日期：1995-03-01 00:00:00

abstract：:In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

journal_title：Leukemia & lymphoma

authors： Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

更新日期：2011-09-01 00:00:00

abstract：:New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: trea...

journal_title：Leukemia & lymphoma

authors： Swinburn P,Shingler S,Acaster S,Lloyd A,Bonthapally V

更新日期：2015-06-01 00:00:00

abstract：:Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were...

journal_title：Leukemia & lymphoma

authors： Dong LH,Zhang LJ,Wang WJ,Lei W,Sun X,Du JW,Gao X,Li GP,Li YF

更新日期：2016-07-01 00:00:00

abstract：:Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refrac...

journal_title：Leukemia & lymphoma

authors： Sorigue M,Bishton M,Domingo-Domenech E,McMillan A,Prusila R,García O,Kuusisto M,Condom M,Tapia G,Ribera JM,Kuittinen O,Fox CP,Sancho JM

更新日期：2019-10-01 00:00:00

abstract：:The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

journal_title：Leukemia & lymphoma

authors： Chattopadhyay A,Abecassis I,Redner RL

更新日期：2015-01-01 00:00:00

abstract：:Patients with hematological malignancies who relapse after bone marrow transplantation (BMT) are often treated with donor lymphocyte infusion. However, this procedure often results in graft-versus-host disease (GVHD). While, Dendritic cells (DCs), which present antigens to naive T cells, have been used in the immunoth...

journal_title：Leukemia & lymphoma

authors： Fujii S,Shimizu K,Fujimoto K,Kiyokawa T,Tsukamoto A,Sanada I,Kawano F

更新日期：2001-07-01 00:00:00

abstract：:Although lymphoma is one of the few solid tumours for which chemotherapy can be curative, the treatment of refractory lymphoma remains a major clinical problem. P-glycoprotein (Pgp), the drug efflux pump encoded by the MDR-1 gene is associated with multidrug resistance in several laboratory models of drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Sandor V,Wilson W,Fojo T,Bates SE

更新日期：1997-12-01 00:00:00

abstract：:Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

journal_title：Leukemia & lymphoma

authors： Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

更新日期：2006-10-01 00:00:00

abstract：:The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

journal_title：Leukemia & lymphoma

authors： Montillo M,Tedeschi A,Centurioni R,Leoni P

更新日期：1997-05-01 00:00:00

abstract：:Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

journal_title：Leukemia & lymphoma

authors： Fung KL,Liang RH,Chan GC

更新日期：2010-03-01 00:00:00